Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
61.65
-1.68 (-2.65%)
At close: Oct 6, 2026, 4:00 PM EDT
61.13
-0.52 (-0.84%)
Pre-market: Oct 7, 2026, 5:17 AM EDT
Disc Medicine Employees
Disc Medicine had 165 employees as of June 30, 2026. The number of employees increased by 40 or 32.00% compared to the same quarter last year.
Employees
165
Change
40
Growth
32.00%
Revenue / Employee
n/a
Profits / Employee
-$1,490,230
Market Cap
2.37B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 165 | 40 | 32.00% | 165 | 0 |
| Mar 31, 2026 | 154 | 60 | 63.83% | 154 | 0 |
| Dec 31, 2025 | 155 | 71 | 84.52% | 155 | 0 |
| Sep 30, 2025 | 142 | 60 | 73.17% | 142 | 0 |
| Jun 30, 2025 | 125 | 47 | 60.26% | 125 | 0 |
| Mar 31, 2025 | 94 | 16 | 20.51% | 94 | 0 |
| Dec 31, 2024 | 84 | 10 | 13.51% | 84 | 0 |
| Sep 30, 2024 | 82 | 22 | 36.67% | 82 | 0 |
| Jun 30, 2024 | 78 | 23 | 41.82% | 78 | 0 |
| Mar 31, 2024 | 78 | 27 | 52.94% | 78 | 0 |
| Dec 31, 2023 | 74 | 28 | 60.87% | 74 | 0 |
| Sep 30, 2023 | 60 | 22 | 57.89% | 60 | 0 |
| Jun 30, 2023 | 55 | 17 | 44.74% | 55 | 0 |
| Mar 31, 2023 | 51 | 13 | 34.21% | 51 | 0 |
| Dec 31, 2022 | 46 | - | - | 46 | 0 |
| Jun 30, 2022 | 38 | - | - | 37 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Beam Therapeutics | 540 |
| Maravai LifeSciences Holdings | 415 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Immunome | 247 |
IRON News
- 21 days ago - Disc Medicine price target raised to $86 from $79 at Wells Fargo - TheFly
- 21 days ago - Disc Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 22 days ago - Disc Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 26 days ago - Disc Medicine Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 27 days ago - Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients - TheFly
- 27 days ago - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting - GlobeNewsWire
- 27 days ago - Disc Medicine Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 27 days ago - Disc Medicine Slides: Corporate presentation - Filings